🔗 Share this article

A shadow market for unapproved weight-loss medications is being driven by TikTok fitness influencers and sellers on communication apps, according to recent findings.

Experimental Drug Acquiring Traction Via Social Media

The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its alleged weight-reducing properties. Followers are encouraged to contact these accounts directly for supplier links, while also obtaining promotional offers.

Thriving Trade on Social Networks

Additionally, a flourishing market exists on Telegram, where groups with thousands of members share “before and after” images, administration instructions and claims of next-day UK delivery. Vendors promote the substance there before redirecting customers to WhatsApp for transactions.

Understanding Retatrutide

Retatrutide is an experimental injection developed by US drugmaker Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could help patients lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed online as the successor to Ozempic.

Medical Professionals Express Worries

However, physicians and pharmacists have cautions that the sale of what is still an unlicensed drug in the UK is worrisome and could lead to individuals administering products of uncertain source.

Some experts stated the demand for retatrutide could be connected to the increasing cost of approved slimming products such as Mounjaro.

Legal Status and Enforcement

Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be promoted or distributed for personal consumption under the British medical regulations.

Several influencers attempt to sidestep the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still violate medicines, marketing, and consumer laws, potentially leading to penalties, legal action or prison.

Platform Reaction and Material Removal

According to the social media company, the service has removed violative material and banned related keywords and search suggestions. The organization said it was committed to keeping the platform secure and investing in enhancing compliance measures.

Digital Trading Operations

Research also discovered groups with up to nine thousand participants marketing retatrutide using Telegram's built-in search feature, which operates like a online catalog. Typing “retatrutide” immediately displays groups with thousands of members, populated with images of weight loss, positive reviews and detailed instructions for preparing or administering at home.

Within minutes of entering one group, a vendor shared contact information, where most purchases occur. The seller sent an instruction manual and promised delivery within two days. When questioned whether the substance was genuine, one seller said: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. Not one inquired about weight, health issues or past usage.

Item Details and Pricing

Inside these communities, posts show black plastic parcels with postal service stickers, claiming to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, prepared at home with sterile water, or pre-filled pens typically sold at £160 for 20 milligrams. When questioned how long a injector should last, sellers give conflicting responses ranging from a several days to “depends on your body”.

Platform Oversight and Safety Measures

A spokesperson for Telegram stated it regularly moderated dangerous content on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“People are administering materials they cannot confirm. Although the research behind this drug is sound, these digital versions may not contain what they advertise,” said Jason Murphy, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of an online medical service linked the surge in interest to current cost increases for approved slimming drugs such as Mounjaro. “With costs increasing, patients are using social media. But fake treatments are extremely dangerous. You cannot know what’s contained or whether the environment they were produced in was sterile,” she said.

Her team has already encountered patients injured by personal administration from unconfirmed suppliers. “We understand the frustration, but buying from Telegram or WhatsApp is taking chances with your well-being,” said Wyllie. “These materials could be impure or improperly measured.”

Manufacturer Statement

A representative from the pharmaceutical company said retatrutide was in third stage clinical trials and had not been reviewed or approved by any government authority globally. “Consequently at this point no one can market [it] for human use,” they said, adding that any product “falsely representing itself as a Lilly investigational product not yet approved … may subject users to potentially significant health risks”.